Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Capalbo
Silvana
S
Spinosa
Giuseppina
G
Franzese
Maria Grazia
MG
Palumbo
Gaetano
G
D000368:Aged; D001565:Benzoates / Q000008:administration & dosage*; D001803:Blood Transfusion; D000077588:Deferasirox; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D019190:Iron Overload / Q000628:therapy; D008297:Male; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D055728:Primary Myelofibrosis / Q000628:therapy; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*
D001565:Benzoates; D006454:Hemoglobins; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox